天中依脉品牌怎么样 申请店铺

更新时间:2024-09-19
天中依脉是哪个国家的品牌?公司简介: 天中依脉集团成立于2009年,现拥有三家全资子公司:天津市天中依脉科技开发有限公司、依脉人工智能医疗科技(天津)有限公司和汇汉依脉智能科技(上海)有限公司。公司坐落于天津滨海高新区华苑产业
天中依脉怎么样

公司简介:

天中依脉集团成立于2009年,现拥有三家全资子公司:天津市天中依脉科技开发有限公司、依脉人工智能医疗科技(天津)有限公司和汇汉依脉智能科技(上海)有限公司。公司坐落于天津滨海高新区华苑产业区,是我国专注于中医四诊客观化技术研究和中医诊疗设备的研发与制造的科技型国内知名高新企业之一。公司具有国内一流的中医诊疗仪器研发团队,完善的生产体系和检验设备,产品质量稳定可靠。公司的脉象仪,舌象仪等产品获得国家中医药管理局中医诊疗设备2011版第一批推荐品目。

天中依脉是较早专注于中医诊疗客观化的高新技术企业,核心技术脱胎于天津中医药大学、天津大学历届专家及从上世纪80年代开始的“中医客观化技术”研究。依脉人工智能医疗科技(天津)有限公司是天中依脉的全资子公司,致力于发展“中医云脑”智能化云中医服务,参与国家“一带一路”中医文化传播与技术推广,全面支持国家医联体建设、家庭医生签约服务等领域的中医药服务,践行健康中国战略。

 15625675637646365997938.png

2009年创立至今,天中依脉与国内三十余家高校及高级医疗机构建立了长期深入的科研合作关系,拥有200多项国家专利及软件著作等知识产权,产品服务于500余家医疗机构,成为中医智能行业的领航者。

公司荣誉:

●2009年,参与国家中医诊断仪器国际以及国家行业标准制定

●2009年,参与火星MARS500计划项目

●2011年,参与承担国家973项目

●2011年,舌象仪和脉象仪同时入选国家中医药管理局《中医诊疗设备推荐品目2011版第一批》

●2012年,参与国家自然基金项目

●2012年,参与国家十二五支撑项目

●2013年,获得中国科技部“科技型中小企业技术创新基金”

●2018年,天中依脉“智云中医”中医医联体管理、服务体系上市,并与全国多家中医机构建立合作关系。

公司愿景:

1、中医客观化诊疗技术,中医健康大数据和人工智能科技的国际领导品牌!

2、建立开放、共享、共赢的中医健康数据服务平台,打造中医健康产业生态群。

3、推动先进的中医科技和传统文化走向世界,服务全人类健康!

公司使命:

创新中医科技,传承中医文化,引领健康生活!

Company profile: Tianzhong Yimai group, founded in 2009, now has three wholly-owned subsidiaries: Tianjin Tianzhong Yimai Technology Development Co., Ltd., Yimai artificial intelligence medical technology (Tianjin) Co., Ltd. and Huihan Yimai Intelligent Technology (Shanghai) Co., Ltd. The company is located in Huayuan Industrial Zone, Binhai high tech Zone, Tianjin. It is one of the well-known high-tech enterprises in China, which focuses on the research and development and manufacturing of the four diagnosis and treatment objectification technology of traditional Chinese medicine and the diagnosis and treatment equipment of traditional Chinese medicine. The company has a domestic first-class R & D team of TCM diagnosis and treatment instruments, perfect production system and testing equipment, and stable and reliable product quality. The company's pulse instrument, tongue instrument and other products have won the first batch of recommended items of Chinese medicine diagnosis and treatment equipment 2011 edition of the State Administration of traditional Chinese medicine. Tianzhong Yimai is an early high-tech enterprise focusing on the objectification of TCM diagnosis and treatment. Its core technology was born from the experts of Tianjin University of traditional Chinese medicine, Tianjin University and the research on "objectification technology of TCM" since the 1980s. One belt, one road, China's Tianjin medical company (China) is a wholly-owned subsidiary of the Chinese medicine company. It is committed to the development of the "Yun Nao" intelligent Chinese medicine service, participating in the "one belt and one way" Chinese medicine culture dissemination and technology promotion, and fully supporting the traditional Chinese medicine service in the fields of national medical conjoined construction, family doctor's contract service and so on, and practicing the healthy China strategy. Since its establishment in 2009, Tianzhong Yimai has established a long-term and in-depth scientific research cooperation relationship with more than 30 universities and advanced medical institutions in China. It has more than 200 national patents and software works and other intellectual property rights. Its products serve more than 500 medical institutions and become a leader in the intelligent industry of traditional Chinese medicine. Honors of the company: ● in 2009, participated in the development of international and national industry standards for diagnostic instruments of traditional Chinese medicine ● in 2009, participated in Mars Mars 500 program project ● in 2011, participated in the national 973 project ● in 2011, tongue imager and pulse imager were selected into the first batch of recommended items of Chinese medical diagnosis and treatment equipment 2011 edition by the State Administration of traditional Chinese medicine ● in 2012, participated in the national natural fund project ● 201 2 years, participated in the national 12th Five Year Plan support project ● in 2013, won the "technology innovation fund for small and medium-sized enterprises of science and technology type" of the Ministry of science and technology of China ● in 2018, Tianzhong Yimai "Zhiyun TCM" TCM management and service system went public, and established cooperation with many TCM institutions across the country. Company vision: 1. Objective diagnosis and treatment technology of traditional Chinese medicine, international leading brand of health big data and artificial intelligence technology of traditional Chinese medicine! 2. Establish an open, shared and win-win TCM health data service platform, and build an ecosystem of TCM health industry. 3. Promote the advanced technology of traditional Chinese medicine and traditional culture to the world, and serve the health of all mankind! Mission of the company: innovate TCM technology, inherit TCM culture and lead healthy life!

本文链接: https://brand.waitui.com/93449407c.html 联系电话:022*****2300 立即查看

千城特选小程序码

7×24h 快讯

超百只基金持有人户数大增,广发基金旗下8只产品受青睐

统计发现,今年上半年,共有110只基金的持有人户数相较2023年末增长了10万户以上。据Wind统计,截至2024年6月末,全市场非货币基金持有人户数共计65704万户,相较2023年末略微减少了约60万户。在总体户数有所下降的情况下,实现持有人户数逆势增长的基金就显得难能可贵。据统计,共有110只基金持有人户数相较2023年末增长了10万户以上,分属于42家基金管理人。其中,来自广发基金的产品达到8只,这一数据在42家基金管理人中名列第2。(证券时报)

2小时前

阿拉斯加航空完成对夏威夷航空的收购

据路透,阿拉斯加航空表示,在与美国交通部达成协议后,该公司已完成对夏威夷航空价值19亿美元的收购。(界面)

2小时前

OpenAI聘请Coursera前首席营收官领导教育业务

OpenAI当地时间9月18日表示,已聘请教育科技公司Coursera前首席营收官莉娅·贝尔斯基(Leah Belsky)担任其首任教育总经理。她将负责促进OpenAI的K-12、高等教育和继续教育领域业务。(界面)

2小时前

中原证券:未来股指总体预计将保持震荡格局

36氪获悉,中原证券研报指出,当前上证综指与创业板指数的平均市盈率分别为11.56倍、25.29倍,处于近三年中位数以下水平,市场估值依然处于较低区域,适合中长期布局。未来股指总体预计将保持震荡格局,同时仍需密切关注政策面、资金面以及外部因素的变化情况。建议投资者短线关注房地产、金融以及家电等行业的投资机会。

2小时前

美国SEC主席表示人工智能工具单一化会给金融业带来风险

美国证券交易委员会(SEC)主席Gary Gensler表示,太多的券商和基金经理过度使用同类人工智能系统可能会为未来的动荡埋下伏笔。Gensler周三表示,如果市场参与者“都依赖相同的模型、相同的算法、相同的数据”,未来的金融危机可能会发生。(新浪财经)

2小时前

本页详细列出关于天中依脉的品牌信息,含品牌所属公司介绍,天中依脉所处行业的品牌地位及优势。
咨询